<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2020-2589</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2589</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Роль омега-3 полиненасыщенных жирных кислот в управлении сердечно-сосудистым риском</article-title><trans-title-group xml:lang="en"><trans-title>Role of omega-3 polyunsaturated fatty acids in cardiovascular risk management</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0758-5609</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подзолков</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Podzolkov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Подзолков Валерий Иванович — доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии № 2</p><p>Москва</p></bio><bio xml:lang="en"/><email xlink:type="simple">podzolkov@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9647-1012</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Писарев</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pisarev</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Писарев Михаил Владимирович — кандидат медицинских наук, доцент кафедры факультетской терапии № 2</p><p>Москва</p></bio><bio xml:lang="en"/><email xlink:type="simple">pisarev@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра факультетской терапии №2 Института клинической медицины имени Н.В.Склифосовского, ФГАОУ ВО Первый МГМУ имени И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff><aff xml:lang="en"><institution>N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Института клинической медицины имени Н.В.Склифосовского, ФГАОУ ВО Первый МГМУ имени И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff><aff xml:lang="en"><institution>N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>01</day><month>06</month><year>2020</year></pub-date><volume>19</volume><issue>3</issue><fpage>2589</fpage><lpage>2589</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Подзолков В.И., Писарев М.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Подзолков В.И., Писарев М.В.</copyright-holder><copyright-holder xml:lang="en">Podzolkov V.I., Pisarev M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2589">https://cardiovascular.elpub.ru/jour/article/view/2589</self-uri><abstract><p>В обзоре представлена информация по современной комплексной оценке сердечно-сосудистого риска согласно Российским и европейским рекомендациям, при этом особый упор сделан на остаточный сердечно-сосудистый риск и его главный маркер — атерогенную дислипидемию. Подробно рассмотрен вклад факторов остаточного риска, в частности гипертриглицеридемии, в патогенез сердечно-сосудистых осложнений при сахарном диабете 2 типа и других комплексных метаболических заболеваниях. Приведены актуальные рекомендации по современной терапии гипертриглицеридемии. Обсуждено важное место, которое занимают препараты омега-3 полиненасыщенных жирных кислот в управлении кардиоваскулярными рисками, в контексте результатов недавно завершившихся крупных клинических исследований.</p></abstract><trans-abstract xml:lang="en"><p>The review provides data on a modern cardiovascular risk management according to Russian and European guidelines Particular emphasis is placed on residual cardiovascular risk and related marker — atherogenic dyslipidemia. The contribution of residual risk factors, in particular hypertriglyceridemia, to the pathogenesis of cardiovascular events in type 2 diabetes and other metabolic disorders is considered in depth. Current guidelines on the modern therapy of hypertriglyceridemia are given. The important role of omega-3 polyunsaturated fatty acids in cardiovascular risk management is discussed in the context of recent large clinical trials.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>остаточный сердечно-сосудистый риск</kwd><kwd>омега-3 полиненасыщенные жирные кислоты</kwd><kwd>профилактика</kwd><kwd>триглицериды</kwd><kwd>гиполипидемическая терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>residual cardiovascular risk</kwd><kwd>omega-3 polyunsaturated fatty acids</kwd><kwd>prevention</kwd><kwd>triglycerides</kwd><kwd>lipid-lowering therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">WHO, World Health Organization. Cardiovascular diseases (CVDs), 2017, http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).</mixed-citation><mixed-citation xml:lang="en">WHO, World Health Organization. Cardiovascular diseases (CVDs), 2017, http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41(1):12-85. doi:10.1093/ehjqcco/qcz065.</mixed-citation><mixed-citation xml:lang="en">Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41(1):12-85. doi:10.1093/ehjqcco/qcz065.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Общая заболеваемость взрослого населения России в 2012 году. Статистические материалы. Часть IV. Москва, 2013.</mixed-citation><mixed-citation xml:lang="en">Total incidence of adult population in Russia in 2012. Statistical data. Part IV. Moscow, 2013. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Россия в цифрах 2019. Краткий статистический сборник. М.: Росстат. 2019.</mixed-citation><mixed-citation xml:lang="en">Russia in numbers 2019. Brief statistical collection. Moscow: Rosstat. 2019. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Кухарчук В.В., Ежов М.В., Сергиенко И.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002.</mixed-citation><mixed-citation xml:lang="en">Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian guidelines, VII revision. Atherosclerosis and dyslipidemia. 2020;1(38):7-42. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.</mixed-citation><mixed-citation xml:lang="en">Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144.</mixed-citation><mixed-citation xml:lang="en">Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. doi:10.1016/S0140-6736(12)60367-5.</mixed-citation><mixed-citation xml:lang="en">Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. doi:10.1016/S0140-6736(12)60367-5.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Szummer K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995- 2014. Eur Heart J. 2017;38(41):3056-3065. doi:10.1093/eurheartj/ehx515.</mixed-citation><mixed-citation xml:lang="en">Szummer K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995- 2014. Eur Heart J. 2017;38(41):3056-3065. doi:10.1093/eurheartj/ehx515.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bengaluru Jayanna M, Robinson JG. The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of “real world” practice in people with diabetes. Diabetes Obes Metab. 2019; 21 Suppl 1:17-27. doi:10.1111/dom.13701.</mixed-citation><mixed-citation xml:lang="en">Bengaluru Jayanna M, Robinson JG. The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of “real world” practice in people with diabetes. Diabetes Obes Metab. 2019; 21 Suppl 1:17-27. doi:10.1111/dom.13701.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г.П., Бойцов С.А., Воевода М.И. и др. Коррекция гипертриглицеридемии с целью снижения остаточного риска при заболеваниях, вызванных атеросклерозом. Заключение Совета экспертов Российского кардиологического общества, Российского научного медицинского общества терапевтов, Евразийской ассоциации терапевтов, Национального общества по изучению атеросклероза, Российской ассоциации эндокринологов и Национальной исследовательской лиги кардиологической генетики. Рациональная Фармакотерапия в Кардиологии. 2019;15(2):282-8. doi:10.20996/1819-6446-2019-15-2-282-288.</mixed-citation><mixed-citation xml:lang="en">Arutyunov GP, Boitsov SA, Voevoda MI, et al. Correction of hypertriglyceridemia in order to reduce the residual risk of diseases caused by atherosclerosis. Conclusion of the expert Council of the Russian cardiological society, the Russian scientific medical society of therapists, the Eurasian Association of therapists, the National society for the study of atherosclerosis, the Russian Association of endocrinologists and the National research League of cardiological genetics. Rational Pharmacotherapy in Cardiology. 2019;15(2):282-8. (In Russ.) doi:10.20996/1819-6446-2019-15-2-282-288.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319-35. doi:10.3132/dvdr.2008.046.</mixed-citation><mixed-citation xml:lang="en">Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319-35. doi:10.3132/dvdr.2008.046.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ponte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, et al. Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert’s position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS). Int J Cardiol. 2017;243:516-522. doi:10.1016/j.ijcard.2017.05.059.</mixed-citation><mixed-citation xml:lang="en">Ponte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, et al. Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert’s position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS). Int J Cardiol. 2017;243:516-522. doi:10.1016/j.ijcard.2017.05.059.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345-61. doi:10.1093/eurheartj/ehr112.</mixed-citation><mixed-citation xml:lang="en">Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345-61. doi:10.1093/eurheartj/ehr112.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gitt AK, Drexel H, Feely J, et al. DYSIS Investigators. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19(2):221-30. doi:10.1177/1741826711400545.</mixed-citation><mixed-citation xml:lang="en">Gitt AK, Drexel H, Feely J, et al. DYSIS Investigators. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19(2):221-30. doi:10.1177/1741826711400545.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Halcox JP, Banegas JR, Roy C, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17(1):160. doi:10.1186/s12872-017-0591-5.</mixed-citation><mixed-citation xml:lang="en">Halcox JP, Banegas JR, Roy C, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17(1):160. doi:10.1186/s12872-017-0591-5.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta M, Tummala R, Ghosh RK, et al. An update on pharmacotherapies in diabetic dyslipidemia. Prog Cardiovasc Dis. 2019;62(4):334-341. doi:10.1016/j.pcad.2019.07.006.</mixed-citation><mixed-citation xml:lang="en">Gupta M, Tummala R, Ghosh RK, et al. An update on pharmacotherapies in diabetic dyslipidemia. Prog Cardiovasc Dis. 2019;62(4):334-341. doi:10.1016/j.pcad.2019.07.006.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Guérin M, Le Goff W, Lassel TS, et al. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001;21(2):282-8. doi:10.1161/01.atv.21.2.282.</mixed-citation><mixed-citation xml:lang="en">Guérin M, Le Goff W, Lassel TS, et al. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001;21(2):282-8. doi:10.1161/01.atv.21.2.282.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371(9626):1800-9. doi:10.1016/S0140-6736(08)60768-0.</mixed-citation><mixed-citation xml:lang="en">Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371(9626):1800-9. doi:10.1016/S0140-6736(08)60768-0.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9. doi:10.1001/jama.2012.366.</mixed-citation><mixed-citation xml:lang="en">Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9. doi:10.1001/jama.2012.366.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157(1):111-117.e2. doi:10.1016/j.ahj.2008.08.010.</mixed-citation><mixed-citation xml:lang="en">Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157(1):111-117.e2. doi:10.1016/j.ahj.2008.08.010.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1580-4. doi:10.1016/j.jacc.2013.07.023.</mixed-citation><mixed-citation xml:lang="en">Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1580-4. doi:10.1016/j.jacc.2013.07.023.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724-30. doi:10.1016/j.jacc.2007.10.038.</mixed-citation><mixed-citation xml:lang="en">Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724-30. doi:10.1016/j.jacc.2007.10.038.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104(4):459-63. doi:10.1016/j.amjcard.2009.04.008.</mixed-citation><mixed-citation xml:lang="en">Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104(4):459-63. doi:10.1016/j.amjcard.2009.04.008.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Toth PP, Philip S, Hull M, Granowitz C. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients. Mayo Clin Proc. 2019 Sep;94(9):1670- 1680. doi:10.1016/j.mayocp.2019.03.028.</mixed-citation><mixed-citation xml:lang="en">Toth PP, Philip S, Hull M, Granowitz C. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients. Mayo Clin Proc. 2019 Sep;94(9):1670- 1680. doi:10.1016/j.mayocp.2019.03.028.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mason RP, Libby P, Bhatt DL. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135-1147. doi:10.1161/ATVBAHA.119.313286.</mixed-citation><mixed-citation xml:lang="en">Mason RP, Libby P, Bhatt DL. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135-1147. doi:10.1161/ATVBAHA.119.313286.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-67. doi:10.1016/j.jacc.2011.06.063.</mixed-citation><mixed-citation xml:lang="en">Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-67. doi:10.1016/j.jacc.2011.06.063.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149. doi:10.1186/s12944-017-0541-3.</mixed-citation><mixed-citation xml:lang="en">Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149. doi:10.1186/s12944-017-0541-3.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5-6):385-91.</mixed-citation><mixed-citation xml:lang="en">Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5-6):385-91.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014;27(7):885-96. doi:10.1093/ajh/hpu024.</mixed-citation><mixed-citation xml:lang="en">Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014;27(7):885-96. doi:10.1093/ajh/hpu024.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Mozaffarian D, Geelen A, Brouwer IA, et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation. 2005;112(13):1945-52. doi:10.1161/CIRCULATIONAHA.105.556886.</mixed-citation><mixed-citation xml:lang="en">Mozaffarian D, Geelen A, Brouwer IA, et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation. 2005;112(13):1945-52. doi:10.1161/CIRCULATIONAHA.105.556886.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">O’Keefe JH, Abuissa H, Sastre A, et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol. 2006;97(8):1127-30. doi:10.1016/j.amjcard.2005.11.025.</mixed-citation><mixed-citation xml:lang="en">O’Keefe JH, Abuissa H, Sastre A, et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol. 2006;97(8):1127-30. doi:10.1016/j.amjcard.2005.11.025.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Lancet. 1999;354:447-55.</mixed-citation><mixed-citation xml:lang="en">Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Lancet. 1999;354:447-55.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Weisman D, Beinart R, Erez A, et al. Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduce ventricular arrhythmia. J Interv Card Electrophysiol. 2017;49(3):255-261. doi:10.1007/s10840-017-0267-1.</mixed-citation><mixed-citation xml:lang="en">Weisman D, Beinart R, Erez A, et al. Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduce ventricular arrhythmia. J Interv Card Electrophysiol. 2017;49(3):255-261. doi:10.1007/s10840-017-0267-1.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Grimsgaard S, Bønaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr. 1998;68(1):52-9. doi:10.1093/ajcn/68.1.52.</mixed-citation><mixed-citation xml:lang="en">Grimsgaard S, Bønaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr. 1998;68(1):52-9. doi:10.1093/ajcn/68.1.52.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Ghio S, Scelsi L, Latini R, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail. 2010;12(12):1345-53. doi:10.1093/eurjhf/hfq172.</mixed-citation><mixed-citation xml:lang="en">Ghio S, Scelsi L, Latini R, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail. 2010;12(12):1345-53. doi:10.1093/eurjhf/hfq172.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Peoples GE, Mclennan PL, Howe PR, Groeller H. Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharmacol. 2008;52(6):540-7. doi:10.1097/FJC.0b013e3181911913.</mixed-citation><mixed-citation xml:lang="en">Peoples GE, Mclennan PL, Howe PR, Groeller H. Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharmacol. 2008;52(6):540-7. doi:10.1097/FJC.0b013e3181911913.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Zehr KR, Walker MK. Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: A review. Prostaglandins Other Lipid Mediat. 2018;134:131-140. doi:10.1016/j.prostaglandins.2017.07.005.</mixed-citation><mixed-citation xml:lang="en">Zehr KR, Walker MK. Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: A review. Prostaglandins Other Lipid Mediat. 2018;134:131-140. doi:10.1016/j.prostaglandins.2017.07.005.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221(2):536- 43. doi:10.1016/j.atherosclerosis.2012.01.006.</mixed-citation><mixed-citation xml:lang="en">Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221(2):536- 43. doi:10.1016/j.atherosclerosis.2012.01.006.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Gao LG, Cao J, Mao QX, et al. Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2013;226(2):328-34. doi:10.1016/j.atherosclerosis.2012.10.056.</mixed-citation><mixed-citation xml:lang="en">Gao LG, Cao J, Mao QX, et al. Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2013;226(2):328-34. doi:10.1016/j.atherosclerosis.2012.10.056.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107(10):1170-84. doi:10.1161/CIRCRESAHA.110.223883.</mixed-citation><mixed-citation xml:lang="en">Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107(10):1170-84. doi:10.1161/CIRCRESAHA.110.223883.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">O’Mahoney LL, Matu J, Price OJ, et al. Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol. 2018;17(1):98. doi:10.1186/s12933-018-0740-x.</mixed-citation><mixed-citation xml:lang="en">O’Mahoney LL, Matu J, Price OJ, et al. Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol. 2018;17(1):98. doi:10.1186/s12933-018-0740-x.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Bersch-Ferreira ÂC, Sampaio GR, Gehringer MO, et al. Association between polyunsaturated fatty acids and inflammatory markers in patients in secondary prevention of cardiovascular disease. Nutrition. 2017;37:30-36. doi:10.1016/j.nut.2016.12.006.</mixed-citation><mixed-citation xml:lang="en">Bersch-Ferreira ÂC, Sampaio GR, Gehringer MO, et al. Association between polyunsaturated fatty acids and inflammatory markers in patients in secondary prevention of cardiovascular disease. Nutrition. 2017;37:30-36. doi:10.1016/j.nut.2016.12.006.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">GISSI-HF investigators. Effect of n-3 polyunsaturated acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008; 372(9645):1223-30. doi:10.1016/S0140-6736(08)61239-8.</mixed-citation><mixed-citation xml:lang="en">GISSI-HF investigators. Effect of n-3 polyunsaturated acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008; 372(9645):1223-30. doi:10.1016/S0140-6736(08)61239-8.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018; 7(7):CD003177. doi:10.1002/14651858.CD003177.pub3.</mixed-citation><mixed-citation xml:lang="en">Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018; 7(7):CD003177. doi:10.1002/14651858.CD003177.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Торшин И.Ю., Громова О.А., Кобалава Ж.Д. Об ошибках метаанализов сердечно-сосудистых эффектов омега-3 ПНЖК. Часть 1. Фармакологические и клинические аспекты доказательности в эпоху постгеномных исследований, искусственного интеллекта и анализа больших данных. Эффективная фармакотерапия. 2019;15(9):26-34. doi:10.33978/2307-3586-2019-15-9-26-34.</mixed-citation><mixed-citation xml:lang="en">Torshin IY, Gromova OA, Kobalava JD. About errors of the metaanalyses of cardiovascular effects of omega-3 PUFA. Part 1. Pharmacological and clinical aspects of evidence in the era of postgenomic research, artificial intelligence, and big data analysis. Effective pharmacotherapy. 2019;15(9):26-34. (In Russ.) doi:10.33978/2307-3586-2019-15-9-26-34.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Kris-Etherton PM, Richter CK, Bowen KJ, et al. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. Methodist DeBakey Cardiovasc J. 2019;15(3):171- 178. doi:10.14797/mdcj-15-3-171.</mixed-citation><mixed-citation xml:lang="en">Kris-Etherton PM, Richter CK, Bowen KJ, et al. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. Methodist DeBakey Cardiovasc J. 2019;15(3):171- 178. doi:10.14797/mdcj-15-3-171.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Торшин И.Ю., Громова О.А., Кобалава Ж.Д. О репрессиях ω-3 полиненасыщенных жирных кислот адептами доказательной медицины. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2019;12(2):91-114. doi:10.17749/2070-4909.2019.12.2.91-114.</mixed-citation><mixed-citation xml:lang="en">Torshin IYu, Gromova OA, Kobalava ZhD. On the repression of ω-3 polyunsaturated fatty acids by adherents of evidencebased medicine. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2019;12(2):91- 114. (In Russ.) doi:10.17749/2070-4909.2019.12.2.91-114.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792.</mixed-citation><mixed-citation xml:lang="en">Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Kastelein JJ, Stroes ES. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380(1):89-90. doi: 10.1056/NEJMe1814004</mixed-citation><mixed-citation xml:lang="en">Kastelein JJ, Stroes ES. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380(1):89-90. doi: 10.1056/NEJMe1814004</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
